In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

GLP-1 drugs like Wegovy and Ozempic are designed to treat type 2 diabetes, but are widely known for their effect on weight ...

The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

projected on-label aflibercept 2 mg Q8W; 70% of patients required 0-1 supplemental injection and 57% were injection-free ... the basis of a BLA submission for 4D-150 in DME, based on review of data ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi ...

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple ...

This retrospective case series involved a review of medical records at a single tertiary care center. Charbel Issa and ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

Faricimab demonstrated “rapid improvements” in anatomic features across previously treated and treatment-naïve patients, ...

The FDA granted regenerative medicine advanced therapy designation to 4D-150 for the treatment of diabetic macular edema, according to a press release from 4D Molecular Therapeutics.

“The RMAT designation is based on the review of our results to-date from ... providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal ...